The European Medicines Agency has validated a regulatory submission for arpraziquantel, a potential new treatment for schistosomiasis in young children.
Work on the clinical program has been supported by the Global Health Innovative Technology (GHIT) fund, which has made investments in a public-private partnership designed to tackle the tropical disease, the Pediatric Praziquantel Consortium.
The candidate was developed by Japan’s Astellas Pharma (TYO: 4503), with subsequent optimization from Germany’s Merck KGaA (MRK: DE).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze